This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



human normal immunoglobulin (SCIg) (Hizentra®)


Reference No. 3711

Publication date:
25/07/2018


Appraisal information

human normal immunoglobulin (SCIg) (Hizentra®) 200 mg/ml solution for injection


Company: CSL Behring UK Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 23/07/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, human normal immunoglobulin (SCIg) (Hizentra®) cannot be endorsed for use within NHS Wales for the treatment of patients with chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with IVIg.
Statement of Advice (SOA)
Download